csirt@kutim:~/threat-intel/cve/CVE-2022-39956

Katalog CVE

CVSS 9.8 · Critical EPSS 1,2%

Kerentanan Incorrect Authorization pada owasp modsecurity core rule set, fedoraproject fedora +1 lainnya. Skor CVSS 3.1 9.8 (Critical) menurut NVD.

Deskripsi (NVD)

The OWASP ModSecurity Core Rule Set (CRS) is affected by a partial rule set bypass for HTTP multipart requests by submitting a payload that uses a character encoding scheme via the Content-Type or the deprecated Content-Transfer-Encoding multipart MIME header fields that will not be decoded and inspected by the web application firewall engine and the rule set. The multipart payload will therefore bypass detection. A vulnerable backend that supports these encoding schemes can potentially be exploited. The legacy CRS versions 3.0.x and 3.1.x are affected, as well as the currently supported versions 3.2.1 and 3.3.2. Integrators and users are advised upgrade to 3.2.2 and 3.3.3 respectively. The mitigation against these vulnerabilities depends on the installation of the latest ModSecurity version (v2.9.6 / v3.0.8).

Rincian

Terbit di NVD
20 September 2022
Terakhir diubah
17 Juni 2026
Status NVD
Modified
CVSS 3.1
9.8 (Critical), sumber NVD
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-863: Incorrect Authorization
CWE-116: Improper Encoding or Escaping of Output
EPSS (30 hari)
1,2% peluang dieksploitasi; lebih tinggi dari 67,7% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
owasp owasp modsecurity core rule set Versi 3.0.0 hingga sebelum 3.2.2
owasp owasp modsecurity core rule set Versi 3.3.0 hingga sebelum 3.3.3
fedoraproject fedora Versi 35
fedoraproject fedora Versi 36
fedoraproject fedora Versi 37
debian debian linux Versi 10.0

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:10 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.